In Figure 7, we evaluated the possible drug resistant phenotype(s) of the GFP-high and GFP-low cell sub-populations to 4-OH-Tamoxifen, an FDA-approved drug used in ER(+) breast cancer cells treatment, and Palbociclib, a CDK4/6 inhibitor. Here, CDK4 is linked to breast carcinoma.